Predictive Oncology Inc. (POAI)
NASDAQ: POAI · Real-Time Price · USD
1.060
0.00 (0.00%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Predictive Oncology Revenue
In the year 2024, Predictive Oncology had annual revenue of $1.62M, down -0.24%. Predictive Oncology had revenue of $611.59K in the quarter ending December 31, 2024, with 91.36% growth.
Revenue (ttm)
$1.62M
Revenue Growth
-0.24%
P/S Ratio
3.56
Revenue / Employee
$67,659
Employees
24
Market Cap
9.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.62M | -3.88K | -0.24% |
Dec 31, 2023 | 1.63M | 122.24K | 8.12% |
Dec 31, 2022 | 1.51M | 84.78K | 5.97% |
Dec 31, 2021 | 1.42M | 168.41K | 13.45% |
Dec 31, 2020 | 1.25M | -159.29K | -11.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
POAI News
- 4 weeks ago - Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary - GlobeNewsWire
- 5 weeks ago - Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries - GlobeNewsWire
- 2 months ago - Predictive Oncology Closes Registered Direct Offering - GlobeNewsWire
- 2 months ago - Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing - GlobeNewsWire
- 2 months ago - Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform - Business Wire
- 3 months ago - AIRNA Appoints Matthew Hawryluk as Chief Business Officer - Business Wire
- 3 months ago - Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay - GlobeNewsWire